Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

Trends in Endocrinology and Metabolism

Volumn 27, Issue 7, 2016, Pages 442-445

  van Raalte, Daniël H ^a,b   Verchere, C Bruce ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Beta cell exhaustion; Beta cell protection; Chronic treatment; Glucagon like peptide (GLP) 1 receptor agonists; Insulin secretion

Indexed keywords

AMYLIN; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; LIRAGLUTIDE; ROSIGLITAZONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; SHORT SURVEY; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INSULIN; INSULIN-SECRETING CELLS; SIGNAL TRANSDUCTION;

EID: 84965065052     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.04.009     Document Type: Short Survey

References (15)

1. Halban P.A., et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014, 37:1751-1758.
2. Kahn S.E., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006, 355:2427-2443.
3. Alarcon C., et al. Pancreatic beta-cell adaptive plasticity in obesity increases insulin production but adversely affects secretory function. Diabetes 2016, 65:438-450.
4. Kramer C.K., et al. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013, 1:28-34.
5. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
6. Salehi M., et al. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr. Rev. 2008, 29:367-379.
7. Bunck M.C., et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011, 34:2041-2047.
8. Abdulreda M.H., et al. Liraglutide compromises pancreatic beta cell function in a humanized mouse model. Cell Metab. 2016, 23:541-546.
9. Aston-Mourney K., et al. Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. Diabetologia 2011, 54:1756-1765.
10. Rabuazzo A.M., et al. Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology 1992, 131:1815-1820.
11. Baggio L.L., et al. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 2004, 53(Suppl. 3):S205-S214.
12. Meier J.J., et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015, 38:1263-1273.
13. Ten Kulve J.S., et al. Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes. Diabetes Care 2016, 39:214-221.
14. Kramer C.K., et al. The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA trial. J. Clin. Endocrinol. Metab. 2015, 100:3702-3709.
15. Smits M.M., et al. Effect of 3 years of treatment with exenatide on postprandial glucagon levels. Diabetes Care 2016, 39:e42-e43.